Fragment-based lead discovery and design

Journal of Chemical Information and Modeling

Volumn 54, Issue 3, 2014, Pages 693-704

  Joseph McCarthy, Diane ^a   Campbell, Arthur J ^a   Kern, Gunther ^a   Moustakas, Demetri ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DESIGN OF EXPERIMENTS; DRUG PRODUCTS;

BIOLOGICAL TARGETS; CHEMICAL BIOLOGY; COMPUTATIONAL APPROACH; DRUG DISCOVERY; HIGH THROUGHPUT SCREENING; LEAD GENERATION; SCREENING TECHNIQUES; STATE OF THE ART;

BIOLOGY;

MOLECULAR LIBRARY; PROTEIN;

ANIMAL; CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM; MOLECULAR LIBRARY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHARMACOLOGY; PROCEDURES; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

ANIMALS; CRYSTALLOGRAPHY, X-RAY; DRUG DISCOVERY; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; PROTEINS; SMALL MOLECULE LIBRARIES; SURFACE PLASMON RESONANCE;

EID: 84896940416     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci400731w     Document Type: Review

References (124)

1. Stumpfe, D.; Hu, Y.; Dimova, D.; Bajorath, J. Recent Progress in Understanding Activity Cliffs and Their Utility in Medicinal Chemistry J. Med. Chem. 2013, 57, 18-28
2. Bogan, A. A.; Thorn, K. S. Anatomy of hot spots in protein interfaces J. Mol. Biol. 1998, 280, 1-9
3. Seebeck, B.; Wagener, M.; Rarey, M. From activity cliffs to target-specific scoring models and pharmacophore hypotheses ChemMedChem 2011, 6, 1533
4. Goodford, P. J. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules J. Med. Chem. 1985, 28, 849-857
5. Evensen, E.; Joseph-McCarthy, D.; Weiss, G. A.; Schreiber, S. L.; Karplus, M. Ligand design by a combinatorial approach based on modeling and experiment: application to HLA-DR4 J. Comput. Aided Mol. Des. 2007, 21, 395-418
6. Miranker, A.; Karplus, M. Functionality maps of binding sites: A multiple copy simultaneous search method Proteins 1991, 11, 29-34
7. Bohm, H. J. Ludi-Rule-Based Automatic Design of New Substituents For Enzyme-Inhibitor Leads J. Comput. -Aided Mol. Des. 1992, 6, 593-606
8. Gillet, V. J.; Myatt, G.; Zsoldos, Z.; Johnson, A. P. SPROUT, HIPPO and CAESA: Tools for de novo structure generation and estimation of synthetic accessibility Perspect. Drug Discov. Design 1995, 3, 34-50
9. Verdonk, M. L.; Cole, J. C.; Taylor, R. SuperStar: a knowledge-based approach for identifying interaction sites in proteins J. Mol. Biol. 1999, 289, 1093-1108
10. Carlson, H. A.; Masukawa, K. M.; Rubins, K.; Bushman, F. D.; Jorgensen, W. L.; Lins, R. D.; Briggs, J. M.; McCammon, J. A. Developing a dynamic pharmacophore model for HIV-1 integrase J. Med. Chem. 2000, 43, 2100-2114
11. Imai, T.; Oda, K.; Kovalenko, A.; Hirata, F.; Kidera, A. Ligand mapping on protein surfaces by the 3D-RISM theory: toward computational fragment-based drug design J. Am. Chem. Soc. 2009, 131, 12430-12440
12. Brenke, R.; Kozakov, D.; Chuang, G. Y.; Beglov, D.; Hall, D.; Landon, M. R.; Mattos, C.; Vajda, S. Fragment-based identification of druggable hot spots of proteins using Fourier domain correlation techniques Bioinformatics 2009, 25, 621-627
13. Landon, M.; Lieberman, R.; Hoang, Q.; Ju, S.; Caaveiro, J.; Orwig, S.; Kozakov, D.; Brenke, R.; Chuang, G.; Beglov, D.; Vajda, S.; Petsko, G.; Ringe, D. Detection of ligand binding hot spots on protein surfaces via fragment-based methods: application to DJ-1 and glucocerebrosidase J. Comput.-Aided Molec. Des. 2009, 23, 491-500
14. Joseph-McCarthy, D.; Baber, J. C.; Feyfant, E.; Thompson, D. C.; Humblet, C. Lead optimization via high-throughput molecular docking Curr. Opin. Drug Discov. Devel. 2007, 10, 264-274
15. Lyne, P. D.; Lamb, M. L.; Saeh, J. C. Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring J. Med. Chem. 2006, 49, 4805-4808
16. Thompson, D. C.; Humblet, C.; Joseph-McCarthy, D. Investigation of MM-PBSA rescoring of docking poses J. Chem. Inf. Model. 2008, 48, 1081-1091
17. Chen, Y.; Shoichet, B. K. Molecular docking and ligand specificity in fragment-based inhibitor discovery Nat. Chem. Biol. 2009, 5, 358-364
18. Teotico, D. G.; Babaoglu, K.; Rocklin, G. J.; Ferreira, R. S.; Giannetti, A. M.; Shoichet, B. K. Docking for fragment inhibitors of AmpC beta-lactamase Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 7455-7460
19. Kawatkar, S.; Wang, H.; Czerminski, R.; Joseph-McCarthy, D. Virtual fragment screening: an exploration of various docking and scoring protocols for fragments using Glide J. Comput. Aided Mol. Des. 2009, 23, 527-539
20. de Graaf, C.; Kooistra, A. J.; Vischer, H. F.; Katritch, V.; Kuijer, M.; Shiroishi, M.; Iwata, S.; Shimamura, T.; Stevens, R. C.; de Esch, I. J.; Leurs, R. Crystal structure-based virtual screening for fragment-like ligands of the human histamine H(1) receptor J. Med. Chem. 2011, 54, 8195-8206
21. Feyfant, E.; Cross, J. B.; Paris, K.; Tsao, D. H. Fragment-based drug design Methods Mol. Biol. 2011, 685, 241-252
22. Cavanagh, J.; Fairbrother, W. J.; Palmer, III, A. G.; Skelton, N.; Rance, M. Protein NMR Spectroscopy: Principles and Practice; Elsevier Science & Technology: Oxford/GB, 2006; p 912.
23. Ernst, R. R.; Bodenhausen, G.; Wokaun, A. Principles of Nuclear Magnetic Resonance in One and Two Dimensions; Oxford University Press: England, 1990.
24. Hajduk, P. J.; Olejniczak, E. T.; Fesik, S. W. One-Dimensional Relaxation- and Diffusion-Edited NMR Methods for Screening Compounds That Bind to Macromolecules J. Am. Chem. Soc. 1997, 119, 12257-12261
25. Dalvit, C.; Fogliatto, G.; Stewart, A.; Veronesi, M.; Stockman, B. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability J. Biomol. NMR 2001, 21, 349-359
26. Mayer, M.; Meyer, B. Characterization of ligand binding by saturation transfer difference NMR spectroscopy Angew. Chem., Int. Ed. 1999, 38, 1784-1788
27. Mayer, M.; Meyer, B. Group Epitope Mapping by Saturation Transfer Difference NMR To Identify Segments of a Ligand in Direct Contact with a Protein Receptor J. Am. Chem. Soc. 2001, 123, 6108-6117
28. Billot-Klein, D.; Shlaes, D.; Bryant, D.; Bell, D.; van, H. J.; Gutmann, L. Peptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB type Biochem. J. 1996, 313 (Pt 3) 711-715
29. Cai, M.; Huang, Y.; Sakaguchi, K.; Clore, G. M.; Gronenborn, A. M.; Craigie, R. An efficient and cost-effective isotope labeling protocol for proteins expressed in Escherichia coli J. Biomol. NMR 1998, 11, 97-102
30. Pervushin, K.; Riek, R.; Wider, G.; Wuthrich, K. Attenuated T2 relaxation by mutual cancellation of dipole-dipole coupling and chemical shift anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 12366-12371
31. Bartoli, S.; Fincham, C. I.; Fattori, D. Fragment-based drug design: combining philosophy with technology Curr. Opin. Drug Discov. Devel. 2007, 10, 422-429
32. Rawlins, P. Current trends in label-free technologies. Drug Discov. World 2010, (Fall).
33. Navratilova, I.; Besnard, J.; Hopkins, A. L. Screening for GPCR Ligands Using Surface Plasmon Resonance ACS Med. Chem. Lett. 2011, 2, 549-554
34. Hartshorn, M. J.; Murray, C. W.; Cleasby, A.; Frederickson, M.; Tickle, I. J.; Jhoti, H. Fragment-based lead discovery using X-ray crystallography J. Med. Chem. 2005, 48, 403-413
35. Davies, T. G.; Tickle, I. J. Fragment Screening Using X-Ray Crystallography Top. Curr. Chem. 2011, 1-27
36. Nienaber, V. L.; Richardson, P. L.; Klighofer, V.; Bouska, J. J.; Giranda, V. L.; Greer, J. Discovering novel ligands for macromolecules using X-ray crystallographic screening Nat. Biotechnol. 2000, 18, 1105-1108
37. Verlinde, C. L.; Fan, E.; Shibata, S.; Zhang, Z.; Sun, Z.; Deng, W.; Ross, J.; Kim, J.; Xiao, L.; Arakaki, T. L.; Bosch, J.; Caruthers, J. M.; Larson, E. T.; Letrong, I.; Napuli, A.; Kelly, A.; Mueller, N.; Zucker, F.; Van Voorhis, W. C.; Buckner, F. S.; Merritt, E. A.; Hol, W. G. Fragment-based cocktail crystallography by the medical structural genomics of pathogenic protozoa consortium Curr. Top. Med. Chem. 2009, 9, 1678-1687
38. Spurlino, J. C. Fragment screening purely with protein crystallography Methods Enzymol. 2011, 493, 321-356
39. Stauch, B.; Orts, J.; Carlomagno, T. The description of protein internal motions aids selection of ligand binding poses by the INPHARMA method J. Biomol. NMR 2012, 54, 245-256
40. Orts, J.; Griesinger, C.; Carlomagno, T. The INPHARMA technique for pharmacophore mapping: A theoretical guide to the method J. Magn. Reson. 2009, 200, 64-73
41. Becattini, B.; Culmsee, C.; Leone, M.; Zhai, D.; Zhang, X.; Crowell, K. J.; Rega, M. F.; Landshamer, S.; Reed, J. C.; Plesnila, N.; Pellecchia, M. Structure-activity relationships by interligand NOE-based design and synthesis of antiapoptotic compounds targeting Bid Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 12602-12606
42. Sledz, P.; Silvestre, H. L.; Hung, A. W.; Ciulli, A.; Blundell, T. L.; Abell, C. Optimization of the interligand Overhauser effect for fragment linking: application to inhibitor discovery against Mycobacterium tuberculosis pantothenate synthetase J. Am. Chem. Soc. 2010, 132, 4544-4545
43. Bartoschek, S.; Klabunde, T.; Defossa, E.; Dietrich, V.; Stengelin, S.; Griesinger, C.; Carlomagno, T.; Focken, I.; Wendt, K. U. Drug design for G-protein-coupled receptors by a ligand-based NMR method Angew. Chem., Int. Ed. Engl. 2010, 49, 1426-1429
44. Allen, K. N.; Bellamacina, C. R.; Ding, X. C.; Jeffery, C. J.; Mattos, C.; Petsko, G. A.; Ringe, D. An experimental approach to mapping the binding surfaces of crystalline proteins J. Phys. Chem. 1996, 100, 2605-2611
45. Fitzpatrick, P. A.; Steinmetz, A. C.; Ringe, D.; Klibanov, A. M. Enzyme crystal structure in a neat organic solvent Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 8653-8657
46. Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for protein targets derived from NMR-based screening data J. Med. Chem. 2005, 48, 2518-2525
47. Gupta, A.; Gupta, A. K.; Seshadri, K. Structural Models in the Assessment of Protein Druggability Based on HTS Data J. Comput.-Aided Mol. Des. 2009, 23, 583-592
48. Joseph-McCarthy, D.; Alvarez, J. C. Automated generation of MCSS-derived pharmacophoric DOCK site points for searching multiconformation databases Proteins 2003, 51, 189-202
49. Joseph-McCarthy, D.; Thomas, B. E., 4th; Belmarsh, M.; Moustakas, D.; Alvarez, J. C. Pharmacophore-based molecular docking to account for ligand flexibility Proteins 2003, 51, 172-188
50. Erlanson, D. A.; Braisted, A. C.; Raphael, D. R.; Randal, M.; Stroud, R. M.; Gordon, E. M.; Wells, J. A. Site-directed ligand discovery Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 9367-9372
51. Erlanson, D. A.; Wells, J. A.; Braisted, A. C. Tethering: fragment-based drug discovery Annu. Rev. Biophys. Biomol. Struct. 2004, 33, 199-223
52. Erlanson, D. A.; Arndt, J. W.; Cancilla, M. T.; Cao, K.; Elling, R. A.; English, N.; Friedman, J.; Hansen, S. K.; Hession, C.; Joseph, I.; Kumaravel, G.; Lee, W. C.; Lind, K. E.; McDowell, R. S.; Miatkowski, K.; Nguyen, C.; Nguyen, T. B.; Park, S.; Pathan, N.; Penny, D. M.; Romanowski, M. J.; Scott, D.; Silvian, L.; Simmons, R. L.; Tangonan, B. T.; Yang, W.; Sun, L. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery Bioorg. Med. Chem. Lett. 2011, 21, 3078-3083
53. Chessari, G.; Woodhead, A. J. From fragment to clinical candidate - a historical perspective Drug Discov. Today 2009, 14, 668-675
54. de Kloe, G. E.; Bailey, D.; Leurs, R.; de Esch, I. J. Transforming fragments into candidates: small becomes big in medicinal chemistry Drug Discov. Today 2009, 14, 630-646
55. Carr, R. A. E.; Congreve, M.; Murray, C. W.; Rees, D. C. Fragment-based lead discovery: leads by design Drug Disc Today 2005, 10, 987-992
56. Erlanson, D. A. Fragment-based lead discovery: a chemical update Curr. Opin. Biotechnol. 2006, 17, 643-652
57. Albert, J. S.; Blomberg, N.; Breeze, A. L.; Brown, A. J.; Burrows, J. N.; Edwards, P. D.; Folmer, R. H.; Geschwindner, S.; Griffen, E. J.; Kenny, P. W.; Nowak, T.; Olsson, L. L.; Sanganee, H.; Shapiro, A. B. An integrated approach to fragment-based lead generation: philosophy, strategy and case studies from AstraZenecas drug discovery programmes Curr Top Med Chem 2007, 7, 1600-1629
58. Hajduk, P. J.; Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned Nat. Rev. Drug Discov. 2007, 6, 211-219
59. Lipinski, C.; Hopkins, A. Navigating chemical space for biology and medicine Nature 2004, 432, 855-861
60. Leach, A. R.; Hann, M. M.; Burrows, J. N.; Griffen, E. J. Fragment screening: an introduction Mol. Biosyst 2006, 2, 430-446
61. Fink, T.; Reymond, J. L. Virtual exploration of the chemical universe up to 11 atoms of C, N, O, F: assembly of 26.4 million structures (110.9 million stereoisomers) and analysis for new ring systems, stereochemistry, physicochemical properties, compound classes, and drug discovery J. Chem. Inf. Model. 2007, 47, 342-353
62. Blum, L. C.; Reymond, J. L. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13 J. Am. Chem. Soc. 2009, 131, 8732-8733
63. Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: a useful metric for lead selection Drug Disc Today 2004, 9, 430-431
64. Rees, D. C.; Congreve, M.; Murray, C. W.; Carr, R. Fragment-based lead discovery Nat. Rev. Drug Discov. 2004, 3, 660-672
65. Reynolds, C. H.; Tounge, B. A.; Bembenek, S. D. Ligand binding efficiency: trends, physical basis, and implications J. Med. Chem. 2008, 51, 2432-2438
66. Kuntz, I. D.; Chen, K.; Sharp, K. A.; Kollman, P. A. The maximal affinity of ligands Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 9997-10002
67. Leeson, P. D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry Nat. Rev. Drug Discov. 2007, 6, 881-890
68. Ryckmans, T.; Edwards, M. P.; Horne, V. A.; Correia, A. M.; Owen, D. R.; Thompson, L. R.; Tran, I.; Tutt, M. F.; Young, T. Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis Bioorg. Med. Chem. Lett. 2009, 19, 4406-4409
69. Abad-Zapatero, C.; Metz, J. T. Ligand efficiency indices as guideposts for drug discovery Drug Discov. Today 2005, 10, 464-469
70. Mortenson, P. N.; Murray, C. W. Assessing the lipophilicity of fragments and early hits J. Comput.-Aided Mol. Des. 2011, 25, 663-667
71. Tanaka, D.; Tsuda, Y.; Shiyama, T.; Nishimura, T.; Chiyo, N.; Tominaga, Y.; Sawada, N.; Mimoto, T.; Kusunose, N. A Practical Use of Ligand Efficiency Indices Out of the Fragment-Based Approach: Ligand Efficiency-Guided Lead Identification of Soluble Epoxide Hydrolase Inhibitors J. Med. Chem. 2011, 54, 851-857
72. Wenlock, M. C.; Austin, R. P.; Barton, P.; Davis, A. M.; Leeson, P. D. A comparison of physiochemical property profiles of development and marketed oral drugs J. Med. Chem. 2003, 46, 1250-1256
73. Vieth, M.; Siegel, M. G.; Higgs, R. E.; Watson, I. A.; Robertson, D. H.; Savin, K. A.; Durst, G. L.; Hipskind, P. A. Characteristic physical properties and structural fragments of marketed oral drugs J. Med. Chem. 2004, 47, 224-232
74. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
75. Payne, D. J.; Gwynn, M. N.; Holmes, D. J.; Pompliano, D. L. Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discov. 2007, 6, 29-40
76. Crisman, T. J.; Bender, A.; Milik, M.; Jenkins, J. L.; Scheiber, J.; Sukuru, S. C.; Fejzo, J.; Hommel, U.; Davies, J. W.; Glick, M. Virtual fragment linking: an approach to identify potent binders from low affinity fragment hits J. Med. Chem. 2008, 51, 2481-2491
77. Brough, P. A.; Aherne, W.; Barril, X.; Borgognoni, J.; Boxall, K.; Cansfield, J. E.; Cheung, K. M.; Collins, I.; Davies, N. G.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Finch, H.; Fink, A.; Hayes, A.; Howes, R.; Hubbard, R. E.; James, K.; Jordan, A. M.; Lockie, A.; Martins, V.; Massey, A.; Matthews, T. P.; McDonald, E.; Northfield, C. J.; Pearl, L. H.; Prodromou, C.; Ray, S.; Raynaud, F. I.; Roughley, S. D.; Sharp, S. Y.; Surgenor, A.; Walmsley, D. L.; Webb, P.; Wood, M.; Workman, P.; Wright, L. 4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J. Med. Chem. 2008, 51, 196-218
78. Schulz, M. N.; Landstrom, J.; Bright, K.; Hubbard, R. E. Design of a fragment library that maximally represents available chemical space J. Comput. Aided Mol. Des. 2011, 25, 611-620
79. Congreve, M.; Carr, R.; Murray, C.; Jhoti, H. A rule of three for fragment-based lead discovery? Drug Disc Today 2003, 8, 876-877
80. Teague, S. J.; Davis, A. M.; Leeson, P. D.; Oprea, T. The Design of Leadlike Combinatorial Libraries Angew. Chem., Int. Ed. Engl. 1999, 38, 3743-3748
81. Nilakantan, R.; Immermann, F.; Haraki, K. A novel approach to combinatorial library design Comb. Chem. High Throughput Screen. 2002, 5, 105-110
82. Bemis, G. W.; Murcko, M. A. The properties of known drugs 0.1. Molecular frameworks J. Med. Chem. 1996, 39, 2887-2893
83. Fejzo, J.; Lepre, C. A.; Peng, J. W.; Bemis, G. W.; Ajay; Murcko, M. A.; Moore, J. M. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery Chem. Biol. 1999, 6, 755-769
84. Andrews, P. R.; Craik, D. J.; Martin, J. L. Functional group contributions to drug-receptor interactions J. Med. Chem. 1984, 27, 1648-1657
85. Hann, M. M.; Leach, A. R.; Harper, G. Molecular complexity and its impact on the probability of finding leads for drug discovery J. Chem. Inf. Comput. Sci. 2001, 41, 856-864
86. Baurin, N.; Aboul-Ela, F.; Barril, X.; Davis, B.; Drysdale, M.; Dymock, B.; Finch, H.; Fromont, C.; Richardson, C.; Simmonite, H.; Hubbard, R. E. Design and characterization of libraries of molecular fragments for use in NMR screening against protein targets J. Chem. Inf. Comput. Sci. 2004, 44, 2157-2166
87. Baurin, N.; Baker, R.; Richardson, C.; Chen, I.; Foloppe, N.; Potter, A.; Jordan, A.; Roughley, S.; Parratt, M.; Greaney, P.; Morley, D.; Hubbard, R. E. Drug-like annotation and duplicate analysis of a 23-supplier chemical database totalling 2.7 million compounds J. Chem. Inf. Comput. Sci. 2004, 44, 643-651
88. Baurin, N.; Mozziconacci, J. C.; Arnoult, E.; Chavatte, P.; Marot, C.; Morin-Allory, L. 2D QSAR consensus prediction for high-throughput virtual screening. An application to COX-2 inhibition modeling and screening of the NCI database J. Chem. Inf. Comput. Sci. 2004, 44, 276-285
89. Leach, A. R.; Hann, M. M. Molecular complexity and fragment-based drug discovery: ten years on Curr. Opin. Chem. Biol. 2011, 15, 489-496
90. Blomberg, N.; Cosgrove, D. A.; Kenny, P. W.; Kolmodin, K. Design of compound libraries for fragment screening J. Comput. Aided Mol. Des. 2009, 23, 513-525
91. Haigh, J. A.; Pickup, B. T.; Grant, J. A.; Nicholls, A. Small molecule shape-fingerprints J. Chem. Inf. Model. 2005, 45, 673-684
92. Hung, A. W.; Ramek, A.; Wang, Y.; Kaya, T.; Wilson, J. A.; Clemons, P. A.; Young, D. W. Route to three-dimensional fragments using diversity-oriented synthesis Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 6799-6804
93. Shapiro, A. B.; Walkup, G. K.; Keating, T. A. Correction for interference by test samples in high-throughput assays J. Biomol. Screen. 2009, 14, 1008-1016
94. Coan, K. E.; Shoichet, B. K. Stoichiometry and physical chemistry of promiscuous aggregate-based inhibitors J. Am. Chem. Soc. 2008, 130, 9606-9612
95. Jencks, W. P. On the attribution and additivity of binding energies Proc. Natl. Acad. Sci. U.S.A. 1981, 78, 4046-4050
96. Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins: SAR by NMR Science 1996, 274, 1531-1534
97. Lauri, G.; Bartlett, P. A. Caveat-a Program to Facilitate the Design of Organic- Molecules J. Comput.-Aided Mol. Des. 1994, 8, 51-66
98. Eisen, M. B.; Wiley, D. C.; Karplus, M.; Hubbard, R. E. HOOK: A program for finding novel molecular architectures that satisfy the chemical and steric requirements of a macromolecule binding sites Proteins 1994, 19, 199-221
99. Pearlman, D.; Murcko, M. CONCERTS: Dynamic connection of fragments as an approach to de novo ligand design J. Med. Chem. 1996, 39, 1651-1663
100. Schneider, G.; Fechner, U. Computer-based de novo design of drug-like molecules Nat. Rev. Drug Discov. 2005, 4, 649-663
101. Loving, K.; Alberts, I.; Sherman, W. Computational approaches for fragment-based and de novo design Curr. Top. Med. Chem. 2010, 10, 14-32
102. Pierce, A. C.; Rao, G.; Bemis, G. W. BREED: Generating novel inhibitors through hybridization of known ligands. Application to CDK2, p38, and HIV protease J. Med. Chem. 2004, 47, 2768-2775
103. Maass, P.; Schulz-Gasch, T.; Stahl, M.; Rarey, M. Recore: A Fast and Versatile Method for Scaffold Hopping Based on Small Molecule Crystal Structure Conformations J. Chem. Inf. Model. 2007, 47, 390-399
104. Thompson, D. C.; Denny, R. A.; Nilakantan, R.; Humblet, C.; Joseph-McCarthy, D.; Feyfant, E. CONFIRM: connecting fragments found in receptor molecules J. Comput. Aided Mol. Des. 2008, 22, 761-772
105. Dey, F.; Caflisch, A. Fragment-based de novo ligand design by multiobjective evolutionary optimization J. Chem. Inf. Model. 2008, 48, 679-690
106. Moriaud, F.; Doppelt-Azeroual, O.; Martin, L.; Oguievetskaia, K.; Koch, K.; Vorotyntsev, A.; Adcock, S. A.; Delfaud, F. Computational fragment-based approach at PDB scale by protein local similarity J. Chem. Inf. Model. 2009, 49, 280-294
107. Howard, N.; Abell, C.; Blakemore, W.; Chessari, G.; Congreve, M.; Howard, S.; Jhoti, H.; Murray, C. W.; Seavers, L. C. A.; van Montfort, R. L. Application of fragment screening and fragment linking to the discovery of novel thrombin inhibitors J. Med. Chem. 2006, 49, 1346-1355
108. Howard, S.; Berdini, V.; Boulstridge, J. A.; Carr, M. G.; Cross, D. M.; Curry, J.; Devine, L. A.; Early, T. R.; Fazal, L.; Gill, A. L.; Heathcote, M.; Maman, S.; Matthews, J. E.; McMenamin, R. L.; Navarro, E. F.; OBrien, M. A.; OReilly, M.; Rees, D. C.; Reule, M.; Tisi, D.; Williams, G.; Vinkovic, M.; Wyatt, P. G. Fragment-Based Discovery of the Pyrazol-4-yl Urea (AT9283), a Multitargeted Kinase Inhibitor with Potent Aurora Kinase Activity J. Med. Chem. 2009, 52, 379-388
109. Antonysamy, S.; Hirst, G.; Park, F.; Sprengeler, P.; Stappenbeck, F.; Steensma, R.; Wilson, M.; Wong, M. Fragment-based discovery of JAK-2 inhibitors Bioorg. Med. Chem. Lett. 2009, 19, 279-282
110. Brough, P. A.; Barril, X.; Borgognoni, J.; Chene, P.; Davies, N. G.; Davis, B.; Drysdale, M. J.; Dymock, B.; Eccles, S. A.; Garcia-Echeverria, C.; Fromont, C.; Hayes, A.; Hubbard, R. E.; Jordan, A. M.; Jensen, M. R.; Massey, A.; Merrett, A.; Padfield, A.; Parsons, R.; Radimerski, T.; Raynaud, F. I.; Robertson, A.; Roughley, S. D.; Schoepfer, J.; Simmonite, H.; Sharp, S. Y.; Surgenor, A.; Valenti, M.; Walls, S.; Webb, P.; Wood, M.; Workman, P.; Wright, L. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone J. Med. Chem. 2009, 52, 4794-4809
111. Edwards, P. D.; Albert, J. S.; Sylvester, M.; Aharony, D.; Andisik, D.; Callaghan, O.; Campbell, J. B.; Carr, R. A.; Chessari, G.; Congreve, M.; Frederickson, M.; Folmer, R. H.; Geschwindner, S.; Koether, G.; Kolmodin, K.; Krumrine, J.; Mauger, R. C.; Murray, C. W.; Olsson, L. L.; Patel, S.; Spear, N.; Tian, G. Application of fragment-based lead generation to the discovery of novel, cyclic amidine beta-secretase inhibitors with nanomolar potency, cellular activity, and high ligand efficiency J. Med. Chem. 2007, 50, 5912-5925
112. Geschwindner, S.; Olsson, L. L.; Albert, J. S.; Deinum, J.; Edwards, P. D.; de Beer, T.; Folmer, R. H. Discovery of a novel warhead against beta-secretase through fragment-based lead generation J. Med. Chem. 2007, 50, 5903-5911
113. Eakin, A. E.; Green, O.; Hales, N.; Walkup, G. K.; Bist, S.; Singh, A.; Mullen, G.; Bryant, J.; Embrey, K.; Gao, N.; Breeze, A.; Timms, D.; Andrews, B.; Uria-Nickelsen, M.; Demeritt, J.; Loch, J. T., 3rd; Hull, K.; Blodgett, A.; Illingworth, R. N.; Prince, B.; Boriack-Sjodin, P. A.; Hauck, S.; MacPherson, L. J.; Ni, H.; Sherer, B. Pyrrolamide DNA gyrase inhibitors: fragment-based nuclear magnetic resonance screening to identify antibacterial agents Antimicrob. Agents Chemother. 2012, 56, 1240-1246
114. Joseph-McCarthy, D. Challenges of fragment screening J. Comput. Aided Mol. Des. 2009, 23, 449-451
115. Sun, C.; Petros, A. M.; Hajduk, P. J. Fragment-based lead discovery: challenges and opportunities J. Comput. Aided Mol. Des. 2011, 25, 607-610
116. Hajduk, P. J.; Galloway, W. R.; Spring, D. R. Drug discovery: A question of library design Nature 2011, 470, 42-43
117. Lahiri, S. D. unpublished work.
118. McLaughlin, R.E.; Patten, A.; Fleming, P. R.; Eyermann, C. J.; Spadola, L.; Kern, G.; Joseph-McCarthy, D. unpublished work.
119. Pipeline Pilot; Accelrys, San Diego, CA, 2010.
120. ROCS; OpenEye Scientific Software, Santa Fe, NM, 2010.
121. Glide; Schrodinger, Inc., New York, NY, 2010.
122. Allegrow; Boston De Novo Design, Boston, MA, 2009.
123. MOE; Chemical Computing Group, Montreal, Canada, 2011.
124. BROOD; OpenEye, Santa Fe, NM, 2011.